Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 1Advanced Ovarian Cancer 1

Interventions

pembrolizumab 589Cyclophosphamide 539Magnetic Resonance Spectroscopy 523Radiotherapy 506Specimen Handling 503Nivolumab 407Cisplatin 370Carboplatin 358Biopsy 304Blood Specimen Collection 295Radiosurgery 283Paclitaxel 274Surveys and Questionnaires 268Standard of Care 266Gemcitabine 265fludarabine 261Dexamethasone 258Drug Therapy 256venetoclax 246Bevacizumab 246Oxaliplatin 206Rituximab 195Capecitabine 194Radiation 189Fluorouracil 186Ipilimumab 184durvalumab 180Doxorubicin 175atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × senaparib × 1 year × Clear all
NCT07586449 2026-05-14

RESO

Zhejiang Cancer Hospital

Not yet recruiting
500 enrolled
Gynecologic

Ovarian Neoplasms

NCT06617923 2025-10-27

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
18 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07120451 2025-08-13

Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker

Fudan University

Phase 2 Not yet recruiting
37 enrolled
Gynecologic

Advanced Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡